Cite
MLA Citation
A. Dalovisio et al.. “P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA.” HemaSphere, vol. 6, n.d., pp. 788–789. http://access.bl.uk/ark:/81055/vdc_100159756069.0x000009